--- title: "Prime Medicine (PRME) news: going concern and offering" url: "https://aibio.space/companies/prime-medicine/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PRME going concern and offering news: Prime Medicine prices 38,000,000 share offering at $3.30, $125,400,000 gross. Prime Medicine, Inc." --- PRME Prime Medicine, Inc. NASDAQ · United States # Prime Medicine (PRME) news PRME going concern and offering news Financings · 2025-07-30 ## [Prime Medicine prices 38,000,000 share offering at $3.30, $125,400,000 gross](https://aibio.space/news/prime-medicine-prices-38-000-000-share-offering-3-30-125-400-000-gross/) Prime sold 38,000,000 shares at $3.30, below the $3.83 closing price on July 29, 2025. The estimated net proceeds are $120.2 million, and the auditor's 2024 report carries a going-concern paragraph. ## Latest Prime Medicine news We have not published a story on Prime Medicine yet. When there is news, it will appear here. ## Prime Medicine at a glance - **Ticker**: PRME - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $95.1 million ### Related companies - [Elicio Therapeutics](https://aibio.space/companies/elicio-therapeutics/) NASDAQ: ELTX - [Design Therapeutics](https://aibio.space/companies/design-therapeutics/) NASDAQ: DSGN - [Enzolytics](https://aibio.space/companies/enzolytics/) OTC: ENZC - [Kura Oncology](https://aibio.space/companies/kura-oncology/) NASDAQ: KURA - [REBUS HLDGS INC.](https://aibio.space/companies/rebus-hldgs/) OTC: RBSH - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) NASDAQ: SPRB - [Spero Therapeutics](https://aibio.space/companies/spero-therapeutics/) NASDAQ: SPRO ### Also on NASDAQ - [Enlivex](https://aibio.space/companies/enlivex/) ENLV - [Prothena Corporation](https://aibio.space/companies/prothena/) PRTA - [Odyssey Therapeutics](https://aibio.space/companies/odyssey-therapeutics/) ODTX - [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NBP - [Dyadic International](https://aibio.space/companies/dyadic-international/) DYAI - [MeiraGTx Holdings](https://aibio.space/companies/meiragtx/) MGTX ## What Prime Medicine does Prime Medicine is a biotechnology company developing genetic medicines based on Prime Editing, a gene editing approach that makes targeted DNA modifications without double-stranded breaks. Prime Editing uses a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA). Its wholly owned in vivo programs target liver diseases and cystic fibrosis (CF), with the CF program supported by the Cystic Fibrosis Foundation. The lead program, PM577, is designed to correct the H1069Q mutation in the ATP7B gene for Wilson Disease and is supported by preclinical data in animal models. PM647 is being advanced for alpha-1 antitrypsin deficiency (AATD). Partnered ex vivo programs with Bristol-Myers Squibb apply Prime Editing to T-cell engineering. Early clinical data from the ex vivo program PM359 for CGD demonstrated restoration of functional protein activity in treated patients. The company describes a modular platform with shared delivery and manufacturing pathways across programs. | Product or program | What it is | Stage | |---|---|---| | PM577 | Prime Editor designed to correct the H1069Q mutation in ATP7B for Wilson Disease | preclinical | | PM647 | Liver-targeted program for alpha-1 antitrypsin deficiency | being advanced | | PM359 | Ex vivo Prime Editing program for CGD | early clinical data reported | | CF program | Prime Editing for cystic fibrosis, delivered by lipid nanoparticles or AAV | progressing | Summarised from the company's [10-K filed Mar 3, 2026](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/prme-20251231.htm). ## Prime Medicine annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | | Research and development | [$160.6 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | [$155.3 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | | Net income (loss) | [-$201.1 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | [-$195.9 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | | Cash from operations | [-$162.6 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | [-$122.9 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | | Cash and equivalents | [$63.0 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026053883/) | [$182.5 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/) | | Short-term investments | [$114.6 million](https://www.sec.gov/Archives/edgar/data/1894562/000162828026053883/) | | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $47.5 million, plus short-term investments of $47.6 million, $95.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Prime Medicine Has Prime Medicine issued a going-concern warning? Our latest story on this, dated Jul 30, 2025: "Prime Medicine prices 38,000,000 share offering at $3.30, $125,400,000 gross". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/prime-medicine-prices-38-000-000-share-offering-3-30-125-400-000-gross/). Has Prime Medicine raised money recently? Our latest story on this, dated Jul 30, 2025: "Prime Medicine prices 38,000,000 share offering at $3.30, $125,400,000 gross". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/prime-medicine-prices-38-000-000-share-offering-3-30-125-400-000-gross/). What is the ticker symbol of Prime Medicine? Prime Medicine, Inc. trades under the ticker PRME on NASDAQ. Where is Prime Medicine listed? Prime Medicine, Inc. is listed on NASDAQ. What is the SEC CIK of Prime Medicine? The SEC Central Index Key (CIK) for Prime Medicine, Inc. is 1894562. Its filings are on SEC EDGAR. How many shares does Prime Medicine have outstanding? 181,376,856 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Prime Medicine listed under? Our directory records Prime Medicine, Inc. under United States. What does Prime Medicine do? Our directory classifies Prime Medicine, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Prime Medicine? The ISIN recorded for Prime Medicine, Inc. is US74168J1016. Does aibio.space cover Prime Medicine? aibio.space lists Prime Medicine, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Prime Medicine incorporated? SEC records list its state or country of incorporation as DE. What does Prime Medicine develop? Prime Medicine is a biotechnology company developing genetic medicines based on Prime Editing, a gene editing approach that makes targeted DNA modifications without double-stranded breaks. Prime Editing uses a Cas9 nickase fused to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA). What is PM577 from Prime Medicine? PM577: Prime Editor designed to correct the H1069Q mutation in ATP7B for Wilson Disease Stage: preclinical. What is PM647 from Prime Medicine? PM647: Liver-targeted program for alpha-1 antitrypsin deficiency Stage: being advanced. What was Prime Medicine's revenue last year? $4.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Prime Medicine Members talk about Prime Medicine (PRME). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Prime Medicine, newest first. Each line links the filing it comes from. 1. 2026-03-03 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/prme-20251231.htm) 2. 2025-11-07 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1894562/000162828025050428/primemedicine-sx3asrxnovem.htm) 3. 2025-07-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1894562/000162828025036721/primemedicineprelim424b5ju.htm) 4. 2025-02-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1894562/000162828025008884/prme-20241231.htm) 5. 2024-12-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1894562/000162828024051126/primemedicine-sx3shelf.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PRME on TradingView](https://www.tradingview.com/symbols/NASDAQ-PRME/). ## SEC filings and registration - **SEC name**: Prime Medicine, Inc. - **CIK**: 1894562 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: PRME (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 60 FIRST ST., CAMBRIDGE, MA, 02141 - **Phone**: 617-465-0013 - **Shares outstanding**: 181,376,856 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1894562/000162828026053883/prme-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1894562/000162828026053878/prme-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1894562/000162828026047590/prme-20260706.htm) filed 2026-07-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1894562/000162828026041543/prme-20260605.htm) filed 2026-06-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1894562/000162828026031726/prme-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1894562/000162828026031719/prme-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1894562/000162828026026697/prme-20260421.htm) filed 2026-04-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1894562/000162828026025372/prme-20260407.htm) filed 2026-04-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001894562), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Prime Medicine, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PRME, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Prime Medicine, Inc. - **Ticker**: PRME - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US74168J1016 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PRME/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/prime-medicine/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Prime Medicine (PRME) news: going concern and offering", 2026-10-31, https://aibio.space/companies/prime-medicine/